IL23R_HUMAN
ID IL23R_HUMAN Reviewed; 629 AA.
AC Q5VWK5; C9JGX4; Q4VGP1; Q4VGP2; Q4VGP3; Q4VGP4; Q4VGP5; Q4VGP6; Q5VWK7;
AC Q8IW84; Q8NFQ9; Q96AS1;
DT 12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT 02-NOV-2010, sequence version 3.
DT 03-AUG-2022, entry version 151.
DE RecName: Full=Interleukin-23 receptor;
DE Short=IL-23 receptor;
DE Short=IL-23R;
DE Flags: Precursor;
GN Name=IL23R;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH IL23;
RP IL12RB1; JAK2 AND STAT3, PHOSPHORYLATION, TISSUE SPECIFICITY, SUBCELLULAR
RP LOCATION, AND VARIANT PRO-310.
RC TISSUE=Natural killer cell, and T-cell;
RX PubMed=12023369; DOI=10.4049/jimmunol.168.11.5699;
RA Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J.,
RA Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J.,
RA O'Farrell A.-M., McClanahan T.K., Zurawski S., Hannum C., Gorman D.,
RA Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W.;
RT "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1
RT and a novel cytokine receptor subunit, IL-23R.";
RL J. Immunol. 168:5699-5708(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 5), NUCLEOTIDE SEQUENCE [MRNA]
RP OF 37-629 (ISOFORMS 1; 3 AND 4), TISSUE SPECIFICITY, AND VARIANT PRO-310.
RC TISSUE=Bone marrow;
RX PubMed=16372191; DOI=10.1007/s00251-005-0067-0;
RA Zhang X.-Y., Zhang H.-J., Zhang Y., Fu Y.-J., He J., Zhu L.-P., Wang S.-H.,
RA Liu L.;
RT "Identification and expression analysis of alternatively spliced isoforms
RT of human interleukin-23 receptor gene in normal lymphoid cells and selected
RT tumor cells.";
RL Immunogenetics 57:934-943(2006).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16710414; DOI=10.1038/nature04727;
RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT "The DNA sequence and biological annotation of human chromosome 1.";
RL Nature 441:315-321(2006).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 6 AND 7), AND VARIANT
RP PRO-310.
RC TISSUE=Bone marrow, and Skin;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP INVOLVEMENT IN IBD17, VARIANTS HIS-3; PRO-310 AND GLN-381, AND
RP CHARACTERIZATION OF VARIANT GLN-381.
RX PubMed=17068223; DOI=10.1126/science.1135245;
RA Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S.,
RA Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A.,
RA Dassopoulos T., Bitton A., Yang H., Targan S., Datta L.W., Kistner E.O.,
RA Schumm L.P., Lee A.T., Gregersen P.K., Barmada M.M., Rotter J.I.,
RA Nicolae D.L., Cho J.H.;
RT "A genome-wide association study identifies IL23R as an inflammatory bowel
RT disease gene.";
RL Science 314:1461-1463(2006).
RN [6]
RP VARIANT GLN-381, AND CHARACTERIZATION OF VARIANT GLN-381.
RX PubMed=17587057; DOI=10.1007/s00439-007-0397-0;
RA Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L.,
RA Timms K., Gutin A., Abkevic V., Burden A.D., Lanchbury J., Barker J.N.,
RA Trembath R.C., Nestle F.O.;
RT "Sequence variants in the genes for the interleukin-23 receptor (IL23R) and
RT its ligand (IL12B) confer protection against psoriasis.";
RL Hum. Genet. 122:201-206(2007).
RN [7]
RP INVOLVEMENT IN IBD17, AND VARIANT GLN-381.
RX PubMed=17804789; DOI=10.1073/pnas.0706645104;
RA Raelson J.V., Little R.D., Ruether A., Fournier H., Paquin B.,
RA Van Eerdewegh P., Bradley W.E.C., Croteau P., Nguyen-Huu Q., Segal J.,
RA Debrus S., Allard R., Rosenstiel P., Franke A., Jacobs G., Nikolaus S.,
RA Vidal J.-M., Szego P., Laplante N., Clark H.F., Paulussen R.J.,
RA Hooper J.W., Keith T.P., Belouchi A., Schreiber S.;
RT "Genome-wide association study for Crohn's disease in the Quebec founder
RT population identifies multiple validated disease loci.";
RL Proc. Natl. Acad. Sci. U.S.A. 104:14747-14752(2007).
RN [8]
RP VARIANTS PRO-310 AND GLN-381, AND CHARACTERIZATION OF VARIANT GLN-381.
RX PubMed=18800148; DOI=10.1038/jid.2008.233;
RA Huffmeier U., Lascorz J., Bohm B., Lohmann J., Wendler J., Mossner R.,
RA Reich K., Traupe H., Kurrat W., Burkhardt H., Reis A.;
RT "Genetic variants of the IL-23R pathway: association with psoriatic
RT arthritis and psoriasis vulgaris, but no specific risk factor for
RT arthritis.";
RL J. Invest. Dermatol. 129:355-358(2009).
RN [9]
RP GLYCOSYLATION AT ASN-29; ASN-47; ASN-81; ASN-141; ASN-180; ASN-232; ASN-262
RP AND ASN-273.
RX PubMed=21053369; DOI=10.1002/jms.1858;
RA Zhao J., Liu Y.H., Reichert P., Pflanz S., Pramanik B.;
RT "Glycosylation analysis of interleukin-23 receptor: elucidation of
RT glycosylation sites and characterization of attached glycan structures.";
RL J. Mass Spectrom. 45:1416-1425(2010).
CC -!- FUNCTION: Associates with IL12RB1 to form the interleukin-23 receptor.
CC Binds IL23 and mediates T-cells, NK cells and possibly certain
CC macrophage/myeloid cells stimulation probably through activation of the
CC Jak-Stat signaling cascade. IL23 functions in innate and adaptive
CC immunity and may participate in acute response to infection in
CC peripheral tissues. IL23 may be responsible for autoimmune inflammatory
CC diseases and be important for tumorigenesis.
CC {ECO:0000269|PubMed:12023369}.
CC -!- SUBUNIT: Heterodimer with IL12RB1. In presence of IL23, the heterodimer
CC forms the IL23 receptor. Interacts with JAK2 and in presence of IL23
CC with STAT3. {ECO:0000269|PubMed:12023369}.
CC -!- INTERACTION:
CC Q5VWK5; Q13901: C1D; NbExp=3; IntAct=EBI-10248005, EBI-3844053;
CC Q5VWK5; Q62120: Jak2; Xeno; NbExp=2; IntAct=EBI-10248005, EBI-646604;
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12023369};
CC Single-pass type I membrane protein {ECO:0000269|PubMed:12023369}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=7;
CC Name=1; Synonyms=IL-23R1;
CC IsoId=Q5VWK5-1; Sequence=Displayed;
CC Name=2; Synonyms=IL-23R2-F2;
CC IsoId=Q5VWK5-2; Sequence=VSP_021993;
CC Name=3; Synonyms=IL-23R3-F1;
CC IsoId=Q5VWK5-3; Sequence=VSP_021997, VSP_021998;
CC Name=4; Synonyms=IL-23R2-F1;
CC IsoId=Q5VWK5-4; Sequence=VSP_021994, VSP_021995;
CC Name=5; Synonyms=IL-23R3-F3;
CC IsoId=Q5VWK5-5; Sequence=VSP_021991, VSP_021999;
CC Name=6; Synonyms=IL-23R6;
CC IsoId=Q5VWK5-6; Sequence=VSP_021992, VSP_021996;
CC Name=7; Synonyms=IL-23R5;
CC IsoId=Q5VWK5-7; Sequence=VSP_021990;
CC -!- TISSUE SPECIFICITY: Expressed by monocytes, Th1, Th0, NK and dendritic
CC cells. Isoform 1 is specifically expressed in NK cells.
CC {ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:16372191}.
CC -!- PTM: Phosphorylated in response to IL23. {ECO:0000269|PubMed:12023369}.
CC -!- DISEASE: Inflammatory bowel disease 17 (IBD17) [MIM:612261]: A chronic,
CC relapsing inflammation of the gastrointestinal tract with a complex
CC etiology. It is subdivided into Crohn disease and ulcerative colitis
CC phenotypes. Crohn disease may affect any part of the gastrointestinal
CC tract from the mouth to the anus, but most frequently it involves the
CC terminal ileum and colon. Bowel inflammation is transmural and
CC discontinuous; it may contain granulomas or be associated with
CC intestinal or perianal fistulas. In contrast, in ulcerative colitis,
CC the inflammation is continuous and limited to rectal and colonic
CC mucosal layers; fistulas and granulomas are not observed. Both diseases
CC include extraintestinal inflammation of the skin, eyes, or joints.
CC {ECO:0000269|PubMed:17068223, ECO:0000269|PubMed:17804789}.
CC Note=Disease susceptibility is associated with variants affecting the
CC gene represented in this entry.
CC -!- MISCELLANEOUS: [Isoform 2]: Produced by translation in an alternate
CC frame of the cDNA encoding isoform 4. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 3]: Produced by translation in an alternate
CC frame of the cDNA encoding isoform 5. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 4]: Produced by translation in an alternate
CC frame of the cDNA encoding isoform 2. {ECO:0000305}.
CC -!- MISCELLANEOUS: [Isoform 5]: Produced by translation in an alternate
CC frame of the cDNA encoding isoform 3. {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the type I cytokine receptor family. Type 2
CC subfamily. {ECO:0000305}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAH16829.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF461422; AAM44229.1; -; mRNA.
DR EMBL; AY937250; AAY18345.1; -; mRNA.
DR EMBL; AY937251; AAY18346.1; -; mRNA.
DR EMBL; AY937252; AAY18347.1; -; mRNA.
DR EMBL; AY937253; AAY18348.1; -; mRNA.
DR EMBL; AY937254; AAY18349.1; -; mRNA.
DR EMBL; AY937255; AAY18350.1; -; mRNA.
DR EMBL; AL109843; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AL389925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC016829; AAH16829.1; ALT_INIT; mRNA.
DR EMBL; BC040720; AAH40720.1; -; mRNA.
DR CCDS; CCDS637.1; -. [Q5VWK5-1]
DR RefSeq; NP_653302.2; NM_144701.2. [Q5VWK5-1]
DR RefSeq; XP_005270573.1; XM_005270516.2. [Q5VWK5-2]
DR RefSeq; XP_011539092.1; XM_011540790.2. [Q5VWK5-1]
DR RefSeq; XP_011539093.1; XM_011540791.2. [Q5VWK5-1]
DR PDB; 5MZV; X-ray; 2.80 A; C=1-317.
DR PDB; 6WDQ; X-ray; 3.40 A; C=24-317.
DR PDBsum; 5MZV; -.
DR PDBsum; 6WDQ; -.
DR AlphaFoldDB; Q5VWK5; -.
DR SMR; Q5VWK5; -.
DR BioGRID; 127199; 13.
DR ComplexPortal; CPX-383; Interleukin-23-receptor complex.
DR IntAct; Q5VWK5; 6.
DR STRING; 9606.ENSP00000321345; -.
DR BindingDB; Q5VWK5; -.
DR ChEMBL; CHEMBL4296013; -.
DR GlyGen; Q5VWK5; 9 sites.
DR iPTMnet; Q5VWK5; -.
DR PhosphoSitePlus; Q5VWK5; -.
DR BioMuta; IL23R; -.
DR DMDM; 311033431; -.
DR EPD; Q5VWK5; -.
DR MassIVE; Q5VWK5; -.
DR PaxDb; Q5VWK5; -.
DR PeptideAtlas; Q5VWK5; -.
DR PRIDE; Q5VWK5; -.
DR ProteomicsDB; 65539; -. [Q5VWK5-7]
DR ABCD; Q5VWK5; 3 sequenced antibodies.
DR Antibodypedia; 33405; 502 antibodies from 34 providers.
DR DNASU; 149233; -.
DR Ensembl; ENST00000347310.10; ENSP00000321345.5; ENSG00000162594.16. [Q5VWK5-1]
DR Ensembl; ENST00000395227.2; ENSP00000378652.2; ENSG00000162594.16. [Q5VWK5-7]
DR Ensembl; ENST00000425614.3; ENSP00000387640.2; ENSG00000162594.16. [Q5VWK5-6]
DR GeneID; 149233; -.
DR KEGG; hsa:149233; -.
DR MANE-Select; ENST00000347310.10; ENSP00000321345.5; NM_144701.3; NP_653302.2.
DR UCSC; uc001ddo.4; human. [Q5VWK5-1]
DR CTD; 149233; -.
DR DisGeNET; 149233; -.
DR GeneCards; IL23R; -.
DR HGNC; HGNC:19100; IL23R.
DR HPA; ENSG00000162594; Tissue enhanced (adrenal gland, testis).
DR MalaCards; IL23R; -.
DR MIM; 607562; gene.
DR MIM; 612261; phenotype.
DR neXtProt; NX_Q5VWK5; -.
DR OpenTargets; ENSG00000162594; -.
DR Orphanet; 117; Behcet disease.
DR Orphanet; 206; NON RARE IN EUROPE: Crohn disease.
DR Orphanet; 771; NON RARE IN EUROPE: Ulcerative colitis.
DR PharmGKB; PA134935109; -.
DR VEuPathDB; HostDB:ENSG00000162594; -.
DR eggNOG; ENOG502QUIH; Eukaryota.
DR GeneTree; ENSGT00530000064198; -.
DR HOGENOM; CLU_029854_0_0_1; -.
DR InParanoid; Q5VWK5; -.
DR OMA; NWCHGGI; -.
DR OrthoDB; 144839at2759; -.
DR PhylomeDB; Q5VWK5; -.
DR TreeFam; TF335930; -.
DR PathwayCommons; Q5VWK5; -.
DR Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR Reactome; R-HSA-9020933; Interleukin-23 signaling.
DR SignaLink; Q5VWK5; -.
DR SIGNOR; Q5VWK5; -.
DR BioGRID-ORCS; 149233; 11 hits in 1067 CRISPR screens.
DR ChiTaRS; IL23R; human.
DR GeneWiki; Interleukin-23_receptor; -.
DR GenomeRNAi; 149233; -.
DR Pharos; Q5VWK5; Tchem.
DR PRO; PR:Q5VWK5; -.
DR Proteomes; UP000005640; Chromosome 1.
DR RNAct; Q5VWK5; protein.
DR Bgee; ENSG00000162594; Expressed in secondary oocyte and 25 other tissues.
DR ExpressionAtlas; Q5VWK5; baseline and differential.
DR Genevisible; Q5VWK5; HS.
DR GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR GO; GO:0072536; C:interleukin-23 receptor complex; IDA:BHF-UCL.
DR GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR GO; GO:0043235; C:receptor complex; IDA:MGI.
DR GO; GO:0019955; F:cytokine binding; IBA:GO_Central.
DR GO; GO:0004896; F:cytokine receptor activity; IBA:GO_Central.
DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR GO; GO:0050829; P:defense response to Gram-negative bacterium; IC:BHF-UCL.
DR GO; GO:0006955; P:immune response; IC:ComplexPortal.
DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR GO; GO:0038155; P:interleukin-23-mediated signaling pathway; IEA:GOC.
DR GO; GO:0032693; P:negative regulation of interleukin-10 production; IMP:BHF-UCL.
DR GO; GO:0042104; P:positive regulation of activated T cell proliferation; IC:BHF-UCL.
DR GO; GO:0010536; P:positive regulation of activation of Janus kinase activity; IC:BHF-UCL.
DR GO; GO:0002230; P:positive regulation of defense response to virus by host; IDA:BHF-UCL.
DR GO; GO:0032725; P:positive regulation of granulocyte macrophage colony-stimulating factor production; IC:BHF-UCL.
DR GO; GO:0032729; P:positive regulation of interferon-gamma production; IDA:BHF-UCL.
DR GO; GO:0032735; P:positive regulation of interleukin-12 production; IDA:BHF-UCL.
DR GO; GO:0032740; P:positive regulation of interleukin-17 production; IC:BHF-UCL.
DR GO; GO:0043382; P:positive regulation of memory T cell differentiation; ISS:BHF-UCL.
DR GO; GO:0032819; P:positive regulation of natural killer cell proliferation; IC:BHF-UCL.
DR GO; GO:0051135; P:positive regulation of NK T cell activation; IC:BHF-UCL.
DR GO; GO:0051142; P:positive regulation of NK T cell proliferation; IC:ComplexPortal.
DR GO; GO:0045672; P:positive regulation of osteoclast differentiation; IC:BHF-UCL.
DR GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; IDA:ComplexPortal.
DR GO; GO:0001916; P:positive regulation of T cell mediated cytotoxicity; ISS:BHF-UCL.
DR GO; GO:0042102; P:positive regulation of T cell proliferation; IDA:ComplexPortal.
DR GO; GO:0002827; P:positive regulation of T-helper 1 type immune response; IDA:BHF-UCL.
DR GO; GO:2000330; P:positive regulation of T-helper 17 cell lineage commitment; ISS:BHF-UCL.
DR GO; GO:2000318; P:positive regulation of T-helper 17 type immune response; ISS:BHF-UCL.
DR GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IC:BHF-UCL.
DR GO; GO:0042509; P:regulation of tyrosine phosphorylation of STAT protein; IC:BHF-UCL.
DR GO; GO:0034341; P:response to interferon-gamma; IDA:BHF-UCL.
DR GO; GO:0032496; P:response to lipopolysaccharide; IDA:BHF-UCL.
DR Gene3D; 2.60.40.10; -; 2.
DR InterPro; IPR003961; FN3_dom.
DR InterPro; IPR036116; FN3_sf.
DR InterPro; IPR013783; Ig-like_fold.
DR SUPFAM; SSF49265; SSF49265; 2.
DR PROSITE; PS50853; FN3; 2.
PE 1: Evidence at protein level;
KW 3D-structure; Alternative splicing; Cell membrane; Glycoprotein; Immunity;
KW Inflammatory response; Innate immunity; Membrane; Phosphoprotein; Receptor;
KW Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix.
FT SIGNAL 1..23
FT /evidence="ECO:0000255"
FT CHAIN 24..629
FT /note="Interleukin-23 receptor"
FT /id="PRO_0000268662"
FT TOPO_DOM 24..355
FT /note="Extracellular"
FT /evidence="ECO:0000255"
FT TRANSMEM 356..376
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 377..629
FT /note="Cytoplasmic"
FT /evidence="ECO:0000255"
FT DOMAIN 127..217
FT /note="Fibronectin type-III 1"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT DOMAIN 219..318
FT /note="Fibronectin type-III 2"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT CARBOHYD 29
FT /note="N-linked (GlcNAc...) asparagine; partial"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 47
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 81
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 141
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 180
FT /note="N-linked (GlcNAc...) (high mannose) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 232
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 262
FT /note="N-linked (GlcNAc...) asparagine"
FT /evidence="ECO:0000269|PubMed:21053369"
FT CARBOHYD 273
FT /note="N-linked (GlcNAc...) asparagine; partial"
FT /evidence="ECO:0000269|PubMed:21053369"
FT VAR_SEQ 1..402
FT /note="Missing (in isoform 7)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_021990"
FT VAR_SEQ 1..365
FT /note="Missing (in isoform 5)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021991"
FT VAR_SEQ 1..255
FT /note="Missing (in isoform 6)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_021992"
FT VAR_SEQ 1..254
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021993"
FT VAR_SEQ 165..174
FT /note="LETEEEQQYL -> DTFCSRHFQG (in isoform 4)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021994"
FT VAR_SEQ 175..629
FT /note="Missing (in isoform 4)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021995"
FT VAR_SEQ 256..266
FT /note="RYKATTNQTWN -> MILRPYQPCGT (in isoform 6)"
FT /evidence="ECO:0000303|PubMed:15489334"
FT /id="VSP_021996"
FT VAR_SEQ 349..356
FT /note="DNRGDIGL -> GLKEGSYC (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021997"
FT VAR_SEQ 357..629
FT /note="Missing (in isoform 3)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021998"
FT VAR_SEQ 366..383
FT /note="MLSILSLIGIFNRSFRTG -> MEFWANSCFHLYRAPYFW (in isoform
FT 5)"
FT /evidence="ECO:0000303|PubMed:16372191"
FT /id="VSP_021999"
FT VARIANT 3
FT /note="Q -> H (in dbSNP:rs1884444)"
FT /evidence="ECO:0000269|PubMed:17068223"
FT /id="VAR_029752"
FT VARIANT 175
FT /note="T -> N (in dbSNP:rs11465797)"
FT /id="VAR_047955"
FT VARIANT 310
FT /note="L -> P (in dbSNP:rs7530511)"
FT /evidence="ECO:0000269|PubMed:12023369,
FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16372191,
FT ECO:0000269|PubMed:17068223, ECO:0000269|PubMed:18800148"
FT /id="VAR_029753"
FT VARIANT 381
FT /note="R -> Q (associated with reduced disease
FT susceptibility; has a protective effect against Crohn
FT disease and psoriasis; dbSNP:rs11209026)"
FT /evidence="ECO:0000269|PubMed:17068223,
FT ECO:0000269|PubMed:17587057, ECO:0000269|PubMed:17804789,
FT ECO:0000269|PubMed:18800148"
FT /id="VAR_029754"
FT CONFLICT 46
FT /note="M -> T (in Ref. 2; AAY18346)"
FT /evidence="ECO:0000305"
FT CONFLICT 133
FT /note="C -> R (in Ref. 2; AAY18348)"
FT /evidence="ECO:0000305"
FT CONFLICT 302
FT /note="R -> G (in Ref. 2; AAY18348)"
FT /evidence="ECO:0000305"
FT CONFLICT 475
FT /note="V -> A (in Ref. 2; AAY18347)"
FT /evidence="ECO:0000305"
FT CONFLICT 481
FT /note="N -> D (in Ref. 2; AAY18347)"
FT /evidence="ECO:0000305"
FT CONFLICT 581
FT /note="S -> R (in Ref. 2; AAY18349)"
FT /evidence="ECO:0000305"
FT STRAND 31..38
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 40..43
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 48..54
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 64..68
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 75..81
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 84..91
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 95..104
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 109..122
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 129..136
FT /evidence="ECO:0007829|PDB:5MZV"
FT HELIX 137..139
FT /evidence="ECO:0007829|PDB:6WDQ"
FT STRAND 141..147
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 157..164
FT /evidence="ECO:0007829|PDB:5MZV"
FT TURN 165..167
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 170..177
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 179..182
FT /evidence="ECO:0007829|PDB:5MZV"
FT HELIX 183..185
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 190..200
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 203..206
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 210..213
FT /evidence="ECO:0007829|PDB:5MZV"
FT TURN 214..216
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 217..219
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 223..230
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 233..235
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 237..244
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 249..259
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 266..270
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 278..283
FT /evidence="ECO:0007829|PDB:5MZV"
FT STRAND 290..298
FT /evidence="ECO:0007829|PDB:5MZV"
SQ SEQUENCE 629 AA; 71722 MW; AC63C89E81AABF05 CRC64;
MNQVTIQWDA VIALYILFSW CHGGITNINC SGHIWVEPAT IFKMGMNISI YCQAAIKNCQ
PRKLHFYKNG IKERFQITRI NKTTARLWYK NFLEPHASMY CTAECPKHFQ ETLICGKDIS
SGYPPDIPDE VTCVIYEYSG NMTCTWNAGK LTYIDTKYVV HVKSLETEEE QQYLTSSYIN
ISTDSLQGGK KYLVWVQAAN ALGMEESKQL QIHLDDIVIP SAAVISRAET INATVPKTII
YWDSQTTIEK VSCEMRYKAT TNQTWNVKEF DTNFTYVQQS EFYLEPNIKY VFQVRCQETG
KRYWQPWSSL FFHKTPETVP QVTSKAFQHD TWNSGLTVAS ISTGHLTSDN RGDIGLLLGM
IVFAVMLSIL SLIGIFNRSF RTGIKRRILL LIPKWLYEDI PNMKNSNVVK MLQENSELMN
NNSSEQVLYV DPMITEIKEI FIPEHKPTDY KKENTGPLET RDYPQNSLFD NTTVVYIPDL
NTGYKPQISN FLPEGSHLSN NNEITSLTLK PPVDSLDSGN NPRLQKHPNF AFSVSSVNSL
SNTIFLGELS LILNQGECSS PDIQNSVEEE TTMLLENDSP SETIPEQTLL PDEFVSCLGI
VNEELPSINT YFPQNILESH FNRISLLEK
